TheraCryf |1HFY25 results – Cash guidance confirmed
The first half of FY25 has been a busy one for TheraCryf. The company closed the Chronos acquisition, trebling its pipeline of development assets, and it completed a £0.9m equity raise. The Erasmus University study on SFX-01, the company's lead clinical asset, is making good progress while the granting of a patent covering the company's Orexin-1 molecule by the European Patent Office has just been announced. Despite its advantages, TheraCryf trades on a fraction of the rating of most peers with similar characteristics, has multiple prospective newsflow events due in 2024/25, and has reconfirmed a financial runway through the end of calendar 2025, excluding any milestone payments.Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.